David Moore
Impact in
- Infectious Diseases top 0.1%
- Tuberculosis Research and Epidemiology
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- General Dentistry top 5%
Papers in
-
- Tuberculosis Research and Epidemiology 160
- HIV/AIDS Research and Interventions 6
- COVID-19 Clinical Research Studies 5
- Co-authors
- Robert Hugh Gilman (54 shared papers)Carlton A. Evans (24 shared papers)Jon S. Friedland (20 shared papers)Adrian Roderick Escombe (12 shared papers)Jorge Coronel (37 shared papers)Luz Caviedes (22 shared papers)Eduardo Ticona (18 shared papers)César Ugarte‐Gil (18 shared papers)
- Journals
- PLoS ONE (19 papers)The Lancet (14 papers)The International Journal of Tuberculosis and Lung Disease (12 papers)Clinical Infectious Diseases (10 papers)American Journal of Tropical Medicine and Hygiene (8 papers)
- Partner nations
- United KingdomPeruUnited States
In The Last Decade
David Moore
233 papers receiving 9.6k citations
David Moore's Hit Papers
Peers
Comparison fields: 5 of 170
- Infectious Diseases 6.8k
- General Dentistry 16
- Parasitology 232
- Applied Microbiology and Biotechnology 75
- Epidemiology 735
Countries citing papers authored by David Moore
This map shows the geographic impact of David Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Moore more than expected).
Fields of papers citing papers by David Moore
This network shows the impact of papers produced by David Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Moore. The network helps show where David Moore may publish in the future.
Co-authors
The 25 scholars most cited alongside David Moore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 243 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 1531 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | 2006 | 389 | |
| 4 | 2007 | 335 | |
| 5 | 2015 | 287 | |
| 6 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 7 | Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis Hit paper breakdown → | 2018 | 257 |
| 8 | A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis Hit paper breakdown → | 2022 | 243 |
| 9 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 10 | The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis Hit paper breakdown → | 2022 | 194 |
| 11 | 2009 | 182 | |
| 12 | 2014 | 166 | |
| 13 | 2020 | 158 | |
| 14 | 2016 | 151 | |
| 15 | 2008 | 148 | |
| 16 | 2016 | 135 | |
| 17 | 2004 | 131 | |
| 18 | 2005 | 126 | |
| 19 | 2003 | 116 | |
| 20 | 2007 | 109 |
About David Moore
David Moore is a scholar working on Infectious Diseases, Parasitology, Epidemiology, Virology and Public Health, Environmental and Occupational Health, having authored 243 papers that have together received 10k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (160 papers), Trypanosoma species research and implications (12 papers), HIV Research and Treatment (6 papers), HIV/AIDS Research and Interventions (6 papers), Mobile Health and mHealth Applications (5 papers), COVID-19 Clinical Research Studies (5 papers), Infection Control and Ventilation (5 papers) and Malaria Research and Control (4 papers). The work is most often cited by research in Infectious Diseases (6.8k citations), General Dentistry (16 citations), Parasitology (232 citations), Applied Microbiology and Biotechnology (75 citations) and Epidemiology (735 citations). David Moore has collaborated with scholars based in United Kingdom, Peru and United States. Frequent co-authors include Robert Hugh Gilman, Carlton A. Evans, Jon S. Friedland, Adrian Roderick Escombe, Jorge Coronel, Luz Caviedes, Eduardo Ticona, César Ugarte‐Gil, Louis Grandjean and Marcos Ñavincopa. Their work appears in journals such as PLoS ONE, The Lancet, The International Journal of Tuberculosis and Lung Disease, Clinical Infectious Diseases and American Journal of Tropical Medicine and Hygiene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.